Kardigan, Inc. (KARD)

Kardigan, Inc. is a biotechnology company focused on developing new medicines for cardiovascular disease. It was founded by a team of drug developers with prior experience building cardiovascular programs, and its strategy is to pursue therapies that target the underlying biology of specific heart conditions rather than only managing symptoms.

The company is advancing a pipeline of programs across several cardiovascular indications, with work at various stages of research and clinical development. It is based in the San Francisco Bay Area, and its common stock trades on the Nasdaq. Its SEC filings describe its individual drug candidates and clinical plans in detail.